FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL						
OMB Number:	3235-0104					
Estimated average burden						
hours per response:	0.5					

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

or Section 30(ii) or the investment Company Act of 1940									
Schenkein David P	2. Date of Event Requiring State Month/Day/Yea 12/07/2017	uiring Statement nth/Day/Year) Denali Therapeutics Inc. [DNLI]							
(Last) (First) (Middle) C/O DENALI THERAPEUTICS INC. 151 OYSTER POINT BOULEVARD,			Relationship of Reporting Perso (Check all applicable) X Director	10% Owne	r (Mo	5. If Amendment, Date of Original Filed (Month/Day/Year)			
SECOND FLOOR			Officer (give title below)	Other (spe	6. Ir App	6. Individual or Joint/Group Filing (Check Applicable Line)			
(Street) SOUTH SAN FRANCISCO CA 94080)		y One Reporting Person y More than One erson		
(City) (State) (Zip)									
Table I - Non-Derivative Securities Beneficially Owned									
1. Title of Security (Instr. 4)			2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (I or Indirect (I) (Instr. 5)		t (D) (Insti	4. Nature of Indirect Beneficial Ownership (Instr. 5)			
Common Stock		75,000	D						
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)									
		Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise	5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)			
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security	Direct (D) or Indirect (I) (Instr. 5)			
Series A-1 Preferred Stock	(1)	(1)	Common Stock	105,225	(1)	I	See footnote ⁽²⁾		
Series A-1 Preferred Stock	(1)	(1)	Common Stock	19,774	(1)	I	See footnote ⁽³⁾		
Series A-1 Preferred Stock	(1)	(1)	Common Stock	105,225	(1)	I	See footnote ⁽⁴⁾		
Series A-1 Preferred Stock	(1)	(1)	Common Stock	19,774	(1)	I	See footnote ⁽⁵⁾		

${\bf Explanation\ of\ Responses:}$

- 1. The Series A-1 Preferred Stock shall automatically convert into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.
- 2. The shares are held of record by the David P. Schenkein 2015 Denali Qualified Annuity Trust, for which the Reporting Person serves as a trustee.
- 3. The shares are held of record by the David P. Schenkein 2004 Revocable Trust, for which the Reporting Person serves as a trustee.
- 4. The shares are held of record by the Amy P. Schenkein 2015 Denali Qualified Annuity Trust, for which the Reporting Person serves as a trustee.
- 5. The shares are held of record by the Amy P. Schenkein 2004 Revocable Trust, for which the Reporting Person serves as a trustee.

Remarks:

Exhibit 24 - Power of Attorney

/s/ Tyler Nielsen, by power of attorney 12/07/2017

** Signature of Reporting Person D

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

The undersigned, as a Section 16 reporting person of Denali Therapeutics Inc. (the "Company"), hereby constitutes and appoints Ryan J. Watts, Steve E. Krognes, Alexander Schuth and Tyler Nielsen, and each of them, as the undersigned's true and lawful attorney-in-fact to:

- 1. prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain EDGAR codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC;
- 2. complete and execute Forms 3, 4 and 5 and other forms and all amendments thereto as such attorney-in-fact shall in his discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the undersigned's ownership, acquisition or disposition of securities of the Company; and
- 3. do all acts necessary in order to file such forms with the SEC, any securities exchange or national association, the Company and such other person or agency as the attorneys-in-fact shall deem appropriate.

The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 (as amended).

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 27th day of November, 2017.

Signature: /s/ David Schenkein

Print Name: David Schenkein